SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UpDog ($UPDOG.X) is trending, and the community is actively engaging in the classic "What's UpDog?" joke, driving much of the conversation. This meme coin on the Solana network, with locked liquidity and a dedicated community, is striving to be the top dog. Amidst the humor, some users are questioning the token's utility and suggesting that the trending status might be artificially driven.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

$CAW.X is trending as the community rallies around the 'crow with knife' meme, calling it the only option for generational wealth. Discussions highlight its strong community, deflationary mechanisms, and expansion across multiple chains. The focus remains on community engagement and the potential for significant growth within the meme coin sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to positive Phase 2 trial results for its hidradenitis suppurativa treatment, sonelokimab, generating significant community excitement. Discussions revolve around the drug's potential efficacy and a possible acquisition, with some speculating on buyout prices and comparing it to competitor data. The stock's high short interest and potential for a squeeze are also being actively discussed.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas ($PANDU.X) is trending, with community members highlighting its recent listing on MEXC and drawing comparisons to other successful meme coins. Bullish sentiment is fueled by perceived solid fundamentals and the project's NFT ranking, with many urging others to research the token. Some users are also discussing preferred wallets for holding $PANDU.X.

BRETT the dancer, gamer, and cultural icon of BASE chain (some like to call me the PEPE of BASE).

Brett

BRETT.X is trending as the community discusses its potential, particularly within the Base ecosystem, while comparing it to other meme coins like TOSHI.X and JTRAMBO. Bullish sentiment is fueled by technical analysis suggesting upside continuation and speculation around a possible Binance or Coinbase listing. Some traders are suggesting it might be time to accumulate $BRETT.X

A composable native asset bridge with unified liquidity and instant guaranteed finality

Stargate

Stargate is trending due to news of LayerZero's acquisition, with a community vote passing for STG holders to convert to ZRO. There's also buzz around the token's role in bridging and burning $CAW.X, with some users highlighting Hyperliquid's new direct deposit feature via Stargate.

LayerZero

LayerZero is trending due to its role in enabling cross-chain functionality, particularly with meme coin $CAW.X. The community is highlighting $CAW.X as the first Cronos project to utilize LayerZero, similar to how $USDC.X and $PEPE.X use it, expressing bullish sentiment and discussing its multichain capabilities.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors discuss its potential turnaround, drawing comparisons to AMD's earlier growth. A recent video highlighting BlackBerry's prospects is circulating, with the community focused on the company's QNX technology and anticipation for upcoming earnings. Optimism is building around partnerships and profitability.

WeRide, Inc. is a holding company, which engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers, and related sensor suites. The company was founded by Tony Xu Han and Yan Li on March 13, 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WRD is trending as investors discuss NVIDIA's Q4 2024 share purchase and a strategic equity investment from Grab, anticipating market impact and potential deployments. The community is weighing these developments against concerns about Chinese EV export regulations and comparing WRD's progress to competitors like Pony.ai, focusing on profitability timelines and key partnerships.

Doodles is a next-generation entertainment company focused on immersive storytelling through the creation and distribution of live and digital experiences, original content, and lifestyle products.  Doodles mission is to define the standard for immersive storytelling and color the world with joy.

Doodle Inu

Doodle Inu ($DOOD.X) is trending as the community rallies around a potential breakout, particularly a push towards the 50 mark.  Enthusiasm is fueled by recent price appreciation and comparisons to other meme coins, with some speculating on future collaborations and airdrops.  However, some users are expressing concerns about bot activity and potential pullbacks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies IQVIA and Flagship Pioneering Announce Strategic Collaboration to...

Mineralys Therapeutics Inc. (195% increase in followers)Radnor, Pennsylvania-based Mineralys is a clinical-stage biopharmaceutical company developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other conditions linked to dysregulated aldosterone.Its lead candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor designed for cardiorenal conditions.Last month, Mineralys reported positive topline results from its Phase 3 Launch-HTN and Phase 2 Advance-HTN trials evaluating lorundrostat for uncontrolled and resistant hypertension. Both studies met their primary efficacy endpoints with statistical significance.&nbsp;In February, Mineralys reported a smaller-than-expected quarterly loss and disclosed that cash, cash equivalents, and investments stood at $198.2 million as of Dec. 31, 2024, which it expects to support clinical studies and corporate operations through the first quarter of 2026.The stock has gained over 28% year-to-date, with short interest at 4.5%, according to Koyfin.Sana Biotechnology Inc. (177% increase in followers)Sana focuses on developing engineered cell therapies to repair or replace damaged or missing cells, as well as control and modify genes.This year, the company has attracted significant investor interest following a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes. In January, it demonstrated that its hypoimmune edits enabled islet cell transplants to survive without immunosuppression, a result that drew praise from analysts.Last month, Citizens JMP upgraded Sana's stock, citing the validation of its Hypoimmune platform in type 1 diabetes, upcoming SC291 data in autoimmune diseases expected in 2025, and a strong cash position of $152.5 million. The firm considers Sana undervalued.Jefferies notes that Sana has three assets in development across different disease areas and projects peak adjusted revenues of $2.8 billion.Sana's stock is up just over 3% year-to-date, with short interest at 17.7%, according to Koyfin.Aeon Biopharma Inc. (132% increase in followers)This is a clinical-stage biopharmaceutical company developing ABP-450, a botulinum toxin complex for treating neurological conditions. Evolus markets the same botulinum toxin complex cosmetically under the name Jeuveau.ABP-450 is already approved as a biosimilar in Mexico and India. Aeon holds exclusive development and distribution rights for therapeutic indications in the U.S., Canada, the EU, the U.K., and select international markets.The stock gained attention this year following a 1-for-72 reverse stock split in March to maintain NYSE American's minimum share price requirement.Last month, Aeon announced that CEO Marc Forth would step down on April 4 to pursue another opportunity, with Chairman Jost Fischer stepping in as interim CEO.Aeon's stock has plunged over 98% year-to-date, with short interest last at 1.7%, according to Koyfin.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1

Three small-cap stocks have intrigued Stocktwits users the most among the biotech sector this year, thanks to promising data from clinical trials and a leadership shuffle.

Equity

Biotech stocks remain a hot sector for retail traders on Stocktwits,&nbsp;which collectively boast over 3.45 million followers.&nbsp;In January, several biotech names saw explosive gains as investors bet on breakthrough treatments, key partnerships, and regulatory milestones.According to Stocktwits data, these five biotech stocks saw the highest surge in retail following this month.CARGO Therapeutics Inc. (CRGX) – 445% Jump In FollowersCARGO Therapeutics, a clinical-stage biotech company focused on cancer treatments, saw its stock collapse even as retail interest surged.&nbsp;In January, the FDA cleared its Investigational New Drug (IND) application for CRG-023, a novel tri-specific CAR T therapy designed to tackle relapse factors in B-cell malignancies.&nbsp;However, the company later announced it would discontinue a Phase II trial of its lead candidate, firi-cel, after an ad hoc safety analysis revealed an unfavorable benefit-risk profile.&nbsp;Wall Street analysts issued downgrades, and CARGO’s stock is on track to plunge more than 76% in January — its worst month since going public in November 2023.&nbsp;Short interest stands at 15.1%, according to Koyfin data.Sana Biotechnology Inc. (SANA) – 185% Jump In FollowersSana Biotechnology, which focuses on engineered cell therapies, captured investor attention with a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes.&nbsp;The company demonstrated earlier this month that its hypoimmune edits allowed islet cell transplant survival without immunosuppression.&nbsp;Analysts praised the findings, driving the stock up roughly 114% in January — its best month since its March 2021 market debut.&nbsp;Short interest is at 16.6%.Silexion Therapeutics Corp. (SLXN) – 92% Jump In FollowersSilexion, an oncology-focused biotech developing RNA interference therapies, gained momentum after releasing preclinical data on a second-generation siRNA candidate, SIL-204.&nbsp;The treatment&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slxn-stock-hits-record-low-after-pricing-5m-offering/chGtwKoRng">showed</a> synergistic efficacy when combined with first-line chemotherapy for pancreatic cancer.&nbsp;Although the stock gained just 2% in January, it marked its best month since November.&nbsp;Short interest remains low at 2.4%.AEON Biopharma Inc. (AEON) – 81% Jump In FollowersAEON Biopharma is developing ABP-450, a botulinum toxin complex similar to Evolus’ Jeuveau, for medical indications such as chronic migraine.&nbsp;Retail traders appeared to buy the dip after AEON priced a $20 million public offering earlier this month, which initially sent shares tumbling.&nbsp;The stock is headed for a 77% drop in January, its worst month since going public via a SPAC merger in July 2023.&nbsp;Short interest is just 0.2%, according to Koyfin.Kairos Pharma (KAPA) – 78% Jump In FollowersKairos Pharma, a clinical-stage biopharmaceutical company, saw retail interest soar this month after breaking key resistance levels and securing crucial investments.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.The stock gained momentum following CEO John Yu’s positive comments at an investor healthcare summit this month and the completion of a $3.5 million PIPE transaction.&nbsp;Kairos shares are set to decline 2.6% in January, marking their worst month since October.&nbsp;Short interest remains&nbsp;negligible at 0.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

This Biotech Penny Stock Is Up 120% This Year. Analysts Think It Can Still Triple From Here in 2025.

With positive results from a clinical trial targeting Type 1 diabetes, Wall Street is feeling hot on this little biotech stock.

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes spiking to 54 times the daily average.&nbsp;The surge followed highly positive analyst reactions to initial data from a groundbreaking type 1 diabetes trial using Sana's experimental cell therapy.The results, unveiled late Tuesday, came from a first-in-human, investigator-led study conducted in collaboration with Uppsala University Hospital.&nbsp;The trial evaluated UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune technology. Notably, the patient did not require immunosuppression for the therapy.&nbsp;Four weeks after transplantation, the study showed the survival and function of transplanted pancreatic beta cells, evidenced by circulating C-peptide levels, which indicate insulin production.&nbsp;Additionally, a mixed meal tolerance test confirmed insulin secretion in response to food, while MRI scans indicated sustained cell graft survival. Importantly, no safety concerns were identified, and the hypoimmune islet cells successfully evaded immune responses.Analysts were quick to praise the results, calling them a potential breakthrough.&nbsp;TD Cowen upgraded Sana to 'Buy' from 'Hold,' citing the proof of concept for hypoimmune technology's immune evasion properties, which it believes de-risks future applications for type 1 diabetes and beyond.&nbsp;Citi referred to the data as a "major scientific advance" for type 1 diabetes patients, highlighting the potential for broader applications in the allogeneic field. The brokerage maintained a 'Buy' rating with a $15 price target.&nbsp;H.C. Wainwright raised its price target for Sana to $11 from $8, increasing the probability of success for its hypoimmune programs and calling the trial results the "best case scenario" for the initial type 1 diabetes update.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SANA_sentiment_and_message_volume_Jan_8_96ba6e683f.png" alt="SANA sentiment and message volume Jan 8.png" width="1318" height="324"><figcaption>SANA sentiment and message volume Jan 8 as of 11:45 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Sana turned 'extremely bullish' (96/100), with the stock climbing into the platform's top five trending symbols.&nbsp;<stembedurl>https://stocktwits.com/RingoZingo/message/599332380</stembedurl><stembedurl>https://stocktwits.com/StonksPacific/message/599334566</stembedurl>Despite the recent surge, Sana's stock remains over 80% below its February 2021 all-time intraday high, although it has gained more than 8% over the past year.&nbsp;Analysts now largely believe the latest data significantly changes the company's risk profile, potentially fueling further appreciation of its stock.For updates and corrections, email newsroom[at]stocktwits[dot]com.

An Asian teenager with type 1 diabetes uses an at home glucometer to test his blood sugar levels. | Image source: Getty Images

Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows Analysts: Retail Erupts In Excitement 

Citi referred to the data as a "major scientific advance" for type 1 diabetes patients, highlighting the potential for broader applications in the allogeneic field.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Futures Slump As Yields, Dollar Soar

Futures Slump As Yields, Dollar Soar

 US equity futures were already rolling over following yesterday's momentum-driven rout, when a the latest report out of CNN (a polar opposite to the...

S&P Futures Climb Ahead of U.S. ADP Jobs Report and FOMC Meeting Minutes

March S&P 500 E-Mini futures (ESH25) are trending up +0.31% this morning, partially rebounding from yesterday’s losses, while investors awaited the Federal Reserve’s December meeting minutes, comments from a Fed official, and a fresh batch of U.S. economic data.

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

Sana Biotechnology Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$3.34
Prev Close	$3.39
Open	$3.39
Dividend Yield	0.00%
50-Day Moving Average	$3.58
Beta	1.99
Avg. Volume	6.16M
PE Ratio	-3.14

52-Week High	$7.30
52-Week Low	$1.26
Market Capitalization	$864.06M
EPS (Annual)	-$1.16
Price to Book	6.28
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SANA
Sana Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SANA News

SANA Sana Biotechnology Inc